Business Bulletins Future News

Vancouver’s STEMCELL Technologies buys Maryland biotech firm

RAEng/Unsplash

STEMCELL Technologies has acquired Maryland-based biotechnology firm Propagenix Inc. The deal is a first for the B.C. company.

“The acquisition of Propagenix is an important step in STEMCELL’s growth journey and an achievement for Canada’s biotechnology industry,” said Dr. Allen Eaves, President and CEO, STEMCELL with the announcement. “Propagenix’s technology has the potential to contribute to big advancements in scientific research in both labs and clinical settings for the treatment of cancer, airway diseases, and other disorders, and we are thrilled to welcome its portfolio into STEMCELL’s product suite.”

The acquisition includes “all of Propagenix’s assets and intellectual property portfolio, its existing business arrangements, as well as its exclusive license to Conditional Reprogramming technology with Georgetown University” according to STEMCELL.

Propagenix was founded in 2014, developing technologies for regenerative medicine, including its patented EpiX™ technology. STEMCELL first licensed the rights to EpiX™ in 2017 for research use.

“We are delighted that the amazing team of scientists at STEMCELL will ensure Propagenix technologies and capabilities for epithelial cell biology are deployed to their fullest to serve the life science research community,” said Dr. Brian Pollok on behalf of Propagenix co-founders.

Founded in 1993, STEMCELL is based in Vancouver with offices in France, the United Kingdom, Australia, Germany, Singapore, China, and Massachusetts. In October 2023, STEMCELL announced it opened a second Canadian sales office in Toronto.